Jiangsu Hengrui Pharmaceuticals Co Ltd, a global pharmaceutical company focusing on scientific and technological innovation, announced on March 25 that it has entered into an exclusive license ...

Pfizer and AbbVie shares declined more than 4%, Merck dropped almost 4%, and Eli Lilly pulled back over 3% in early trading. Daily Merck & Company, Inc. Dow pharmaceutical components are leading ...

The Macomb Group announced that Deacon Industrial Supply will operate fully under The Macomb Group name, marking the final step in the merger that took place in 2023. The combined company now has over ...

Lusaka [Zambia] / Mumbai (Maharashtra) [India], April 7: Merck Foundation, the philanthropic arm of Merck KGaA Germany marks 'World Health Day' 2025 in partnership with Africa's First Ladies who ...

Merck has shared data from the pivotal 3475A-D77 Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together with berahyaluronidase alfa (subcutaneous pembrolizumab). The study ...

Mer­ck KGaA is spend­ing $85 mil­lion to tap glob­al com­mer­cial­iza­tion rights to pim­i­co­tinib, a can­di­date for non-ma­lig­nant tu­mors that it li­censed from Chi­na’s ...

This year's two sessions is a reconfirmation of the confidence that Merck has in China because the Chinese government has set the economic growth target at 5 percent, focusing more on innovation ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia. The ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s patent cliff at bay. In a push to keep the Keytruda gravy train on the ...

German life sciences and pharma company Merck KGaA (MRK: DE) today revealed it has exercised its option with China’s Abbisko Therapeutics (HKEX: 02256) for commercialization of pimicotinib in the US ...

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the Greater China region. Hengrui Pharma will ...

Mer­ck shared Phase 3 da­ta show­ing that an in­jectable ver­sion of its block­buster can­cer drug Keytru­da is com­pa­ra­ble to the ap­proved … ...